Nichi-Iko Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nichi-Iko Pharmaceutical Co., Ltd.
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.
In a year that has seen significant changes throughout the generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders. Meanwhile, companies lower down our ranking have enjoyed mixed fortunes, leading to a number of significant movements in this year’s Generics Bulletin Top 50.
After several lackluster quarters, Towa’s acquisition of Sunsho Pharmaceutical is finally paying off for the Japanese generics firm.
Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.
- Generic Drugs
- OTC, Consumer
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Large Molecule
- Other Names / Subsidiaries
- Elmed Eisai Co., Ltd
- Nichi-Iko Medical Practice Institution Co., Ltd.
- Yakuhan Pharmaceutical Co., Ltd.
- Nichi-Iko Pharma Tech Co., Ltd.
- Omega Laboratories Limited
- Sagent Pharmaceuticals Inc.
- Nihon Iyakuhin Kogyo Co., Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.